JP2011514149A5 - - Google Patents

Download PDF

Info

Publication number
JP2011514149A5
JP2011514149A5 JP2010545219A JP2010545219A JP2011514149A5 JP 2011514149 A5 JP2011514149 A5 JP 2011514149A5 JP 2010545219 A JP2010545219 A JP 2010545219A JP 2010545219 A JP2010545219 A JP 2010545219A JP 2011514149 A5 JP2011514149 A5 JP 2011514149A5
Authority
JP
Japan
Prior art keywords
domain
polypeptide
loop
polypeptide according
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2010545219A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011514149A (ja
JP5889533B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2009/032692 external-priority patent/WO2009099961A2/en
Publication of JP2011514149A publication Critical patent/JP2011514149A/ja
Publication of JP2011514149A5 publication Critical patent/JP2011514149A5/ja
Application granted granted Critical
Publication of JP5889533B2 publication Critical patent/JP5889533B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2010545219A 2008-01-31 2009-01-30 改変された抗体定常ドメイン分子 Active JP5889533B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US6324508P 2008-01-31 2008-01-31
US61/063,245 2008-01-31
PCT/US2009/032692 WO2009099961A2 (en) 2008-01-31 2009-01-30 Engineered antibody constant domain molecules

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014112059A Division JP2014155503A (ja) 2008-01-31 2014-05-30 改変された抗体定常ドメイン分子

Publications (3)

Publication Number Publication Date
JP2011514149A JP2011514149A (ja) 2011-05-06
JP2011514149A5 true JP2011514149A5 (enExample) 2012-01-26
JP5889533B2 JP5889533B2 (ja) 2016-03-22

Family

ID=40613065

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2010545219A Active JP5889533B2 (ja) 2008-01-31 2009-01-30 改変された抗体定常ドメイン分子
JP2014112059A Pending JP2014155503A (ja) 2008-01-31 2014-05-30 改変された抗体定常ドメイン分子

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2014112059A Pending JP2014155503A (ja) 2008-01-31 2014-05-30 改変された抗体定常ドメイン分子

Country Status (7)

Country Link
US (3) US8580927B2 (enExample)
EP (2) EP2594584B1 (enExample)
JP (2) JP5889533B2 (enExample)
CN (2) CN101977932B (enExample)
AU (1) AU2009212747B2 (enExample)
CA (2) CA2713281C (enExample)
WO (1) WO2009099961A2 (enExample)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE423140T1 (de) 2005-01-05 2009-03-15 F Star Biotech Forsch & Entw Synthetische immunoglobulindomänen mit in regionen des moleküls, die sich von den die komplementarität bestimmenden bereichen unterscheiden, modifizierten bindeeigenschaften
AT503889B1 (de) 2006-07-05 2011-12-15 Star Biotechnologische Forschungs Und Entwicklungsges M B H F Multivalente immunglobuline
PL3241842T3 (pl) 2007-06-26 2024-06-10 F-Star Therapeutics Limited Prezentacja środków wiążących
EP2238165B1 (en) * 2008-01-07 2017-07-05 Government of the United States of America, as represented by the Secretary, Department of Health and Human Services Anti-hiv domain antibodies and method of making and using same
US8580927B2 (en) * 2008-01-31 2013-11-12 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Engineered antibody constant domain molecules
EP2113255A1 (en) 2008-05-02 2009-11-04 f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. Cytotoxic immunoglobulin
CA2729591A1 (en) * 2008-06-30 2010-01-07 Boehringer Ingelheim International Gmbh Method for optimizing proteins having the folding pattern of immunoglobulin
EP2451838A1 (en) * 2009-07-09 2012-05-16 f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. Stabilized immunoglobulin constant domains
EP2494061B1 (en) * 2009-10-29 2017-01-25 Janssen Biotech, Inc. Antibody glycosylation variants
AU2011215684A1 (en) * 2010-02-12 2012-08-30 Research Corporation Technologies Multimeric proteins comprising immunoglobulin constant domains
CA2815342A1 (en) * 2010-10-20 2012-04-26 Medimmune, Llc Methods for processing inclusion bodies
AU2012214274B2 (en) * 2011-02-11 2017-02-02 Research Corporation Technologies, Inc. CH2 domain template molecules derived from rational grafting of donor loops onto CH2 scaffolds
US9803210B2 (en) 2011-02-11 2017-10-31 Research Corporation Technologies, Inc. Fusion proteins comprising immunoglobulin constant domain-derived scaffolds
WO2013002362A1 (ja) 2011-06-30 2013-01-03 中外製薬株式会社 ヘテロ二量化ポリペプチド
US9688731B2 (en) * 2011-12-22 2017-06-27 Wisconsin Alumni Research Foundation Isolation and application of BAD-1 for diagnosing infections with Blastomyces dermatitidis
WO2013138643A1 (en) 2012-03-16 2013-09-19 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Soluble engineered monomeric fc
SG11201407017WA (en) * 2012-06-04 2014-12-30 Irm Llc Site-specific labeling methods and molecules produced thereby
EP4310191A3 (en) * 2012-06-14 2024-05-15 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule containing modified fc region
JP6774164B2 (ja) 2012-08-24 2020-10-21 中外製薬株式会社 マウスＦｃγＲＩＩ特異的Ｆｃ抗体
JP6144487B2 (ja) 2012-12-26 2017-06-07 三菱航空機株式会社 フラップの展開装置、及び、航空機
CA2929044A1 (en) 2013-11-11 2015-05-14 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule containing modified antibody variable region
CA2963556C (en) * 2014-10-24 2023-03-14 Research Corporation Technologies, Inc. Small antibody-like polypeptides that bind to epha2 receptor
US11154615B2 (en) 2014-11-11 2021-10-26 Chugai Seiyaku Kabushiki Kaisha Library of antigen-binding molecules including modified antibody variable region
WO2017115828A1 (ja) * 2015-12-29 2017-07-06 国立大学法人東京工業大学 標的結合ペプチドの安定化方法
HUE065861T2 (hu) * 2016-08-26 2024-06-28 Sanofi Sa Szelektív könnyûlánc-párosítást elõsegítõ multispecifikus antitestek
CN110603265B (zh) * 2017-01-09 2024-01-30 莱蒂恩技术公司 用于用抗间皮素免疫治疗癌症的组合物和方法
RS63818B1 (sr) 2017-02-17 2023-01-31 Denali Therapeutics Inc Konstruisani polipeptidi za vezivanje za receptor transferina
JP2020511519A (ja) 2017-03-22 2020-04-16 リサーチ コーポレーション テクノロジーズ インコーポレイテッド 操作された安定なｃｈ２ポリペプチド
EP3612562A2 (en) 2017-04-19 2020-02-26 Institute for Research in Biomedicine Plasmodium sporozoite npdp peptides as vaccine and target novel malaria vaccines and antibodies binding to
JP7357616B2 (ja) 2017-12-05 2023-10-06 中外製薬株式会社 Ｃｄ３およびｃｄ１３７に結合する改変された抗体可変領域を含む抗原結合分子
CA3086098A1 (en) * 2017-12-19 2019-06-27 F-Star Beta Limited Fc binding fragments comprising a pd-l1 antigen-binding site
CN108191974B (zh) * 2017-12-31 2021-04-09 武汉班科生物技术股份有限公司 抗聚集人源IgG抗体CH2结构域突变体及应用
WO2021062012A1 (en) 2019-09-25 2021-04-01 Emory University Use of klk10 and engineered derivatizations thereof
CA3173587A1 (en) 2020-03-31 2021-10-07 Chugai Seiyaku Kabushiki-Kaisha Dll3-targeting multispecific antigen-binding molecules and uses thereof
WO2022067020A1 (en) * 2020-09-24 2022-03-31 The Broad Institute, Inc. Cell-free antibody engineering platform and neutralizing antibodies for sars-cov-2
US20250223379A1 (en) * 2021-01-11 2025-07-10 Adimab, Llc Variant ch3 domains engineered for preferential ch3 heterodimerization, multi-specific antibodies comprising the same, and methods of making thereof
IL311003A (en) 2021-08-25 2024-04-01 Denali Therapeutics Inc Anti-2HER antibodies and methods of using them
WO2023087017A1 (en) * 2021-11-15 2023-05-19 Alector Llc Proteins comprising blood brain barrier (bbb)-binding domains within constant domains
CN116063468A (zh) * 2022-08-30 2023-05-05 武汉班科生物技术有限公司 中和呼吸道合胞病毒的c-型单域抗体及应用
WO2026143022A1 (en) 2024-12-23 2026-07-02 Point Loma Nazarene University Antibody directed enzyme pro-drug therapy (adept) for cancer treatment using an antibody or fragment that binds to a cd206 receptor and 3-cyclopentyl-alpha-phenylalanine-methotrexate

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3060165A (en) 1962-10-23 Preparation of toxic ricin
US4458066A (en) 1980-02-29 1984-07-03 University Patents, Inc. Process for preparing polynucleotides
US4957735A (en) 1984-06-12 1990-09-18 The University Of Tennessee Research Corporation Target-sensitive immunoliposomes- preparation and characterization
US5079163A (en) 1985-03-29 1992-01-07 Cetus Corporation Recombinant ricin toxin fragments
US4689401A (en) 1986-03-06 1987-08-25 Cetus Corporation Method of recovering microbially produced recombinant ricin toxin a chain
US5208021A (en) 1987-10-05 1993-05-04 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Method of preparing diphtheria immunotoxins
US5792458A (en) 1987-10-05 1998-08-11 The United States Of America As Represented By The Department Of Health And Human Services Mutant diphtheria toxin conjugates
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5061620A (en) 1990-03-30 1991-10-29 Systemix, Inc. Human hematopoietic stem cell
US5965709A (en) * 1991-08-14 1999-10-12 Genentech, Inc. IgE antagonists
PT1024191E (pt) 1991-12-02 2008-12-22 Medical Res Council Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
DE69334275D1 (de) 1992-08-21 2009-05-20 Univ Bruxelles Immunoglobuline ohne Leichtkette
WO1994025591A1 (en) 1993-04-29 1994-11-10 Unilever N.V. PRODUCTION OF ANTIBODIES OR (FUNCTIONALIZED) FRAGMENTS THEREOF DERIVED FROM HEAVY CHAIN IMMUNOGLOBULINS OF $i(CAMELIDAE)
EP0739981A1 (en) 1995-04-25 1996-10-30 Vrije Universiteit Brussel Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes
US6828422B1 (en) 1995-08-18 2004-12-07 Morphosys Ag Protein/(poly)peptide libraries
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
US6083715A (en) 1997-06-09 2000-07-04 Board Of Regents, The University Of Texas System Methods for producing heterologous disulfide bond-containing polypeptides in bacterial cells
US7829084B2 (en) * 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
JP4303105B2 (ja) 2001-06-28 2009-07-29 ドマンティス リミテッド 二重特異性リガンドとその利用
CA2832136C (en) 2002-09-27 2015-11-17 Xencor Optimized fc variants and methods for their generation
ITRM20020588A1 (it) 2002-11-21 2004-05-22 Lay Line Genomics Spa Metodo per isolare anticorpi intracellulari neutralizzanti di interazioni proteiche.
JP5087274B2 (ja) 2003-06-30 2012-12-05 ドマンティス リミテッド ポリペプチド
CA2580796C (en) * 2004-09-24 2013-03-26 Amgen Inc. Modified fc molecules having peptides inserted in internal loop regions
AU2005335714B2 (en) 2004-11-10 2012-07-26 Macrogenics, Inc. Engineering Fc antibody regions to confer effector function
ATE423140T1 (de) * 2005-01-05 2009-03-15 F Star Biotech Forsch & Entw Synthetische immunoglobulindomänen mit in regionen des moleküls, die sich von den die komplementarität bestimmenden bereichen unterscheiden, modifizierten bindeeigenschaften
CA2605697A1 (en) * 2005-04-26 2006-11-02 Bioren, Inc. Method of producing human igg antibodies with enhanced effector functions
DK1931709T3 (en) 2005-10-03 2017-03-13 Xencor Inc FC VARIETIES WITH OPTIMIZED FC RECEPTOR BINDING PROPERTIES
JP2009526750A (ja) * 2005-12-22 2009-07-23 セントカー・インコーポレーテツド Ｇｌｐ−１アゴニスト、組成物、方法および使用
AT503889B1 (de) * 2006-07-05 2011-12-15 Star Biotechnologische Forschungs Und Entwicklungsges M B H F Multivalente immunglobuline
WO2008100470A2 (en) * 2007-02-15 2008-08-21 Transtech Pharma, Inc. Rage - immunoglobulin fusion proteins
MX2009012609A (es) 2007-05-22 2009-12-07 Amgen Inc Composiciones y metodos para producir proteinas de fusion bioactivas.
US8580927B2 (en) * 2008-01-31 2013-11-12 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Engineered antibody constant domain molecules
AU2011215684A1 (en) 2010-02-12 2012-08-30 Research Corporation Technologies Multimeric proteins comprising immunoglobulin constant domains
AU2012214274B2 (en) * 2011-02-11 2017-02-02 Research Corporation Technologies, Inc. CH2 domain template molecules derived from rational grafting of donor loops onto CH2 scaffolds

Similar Documents

Publication Publication Date Title
JP7568756B2 (ja) プラスミノーゲン活性化因子阻害剤－１（ｐａｉ－１）に対する抗体及びその使用
JP2021020905A5 (enExample)
JP2022177097A (ja) ヘテロ二量体多重特異性抗体フォーマット
JP7496091B2 (ja) 合理的に設計された新規なタンパク質組成物
TWI713942B (zh) 與集落刺激因子１受體（ｃｓｆ１ｒ）結合之抗體類
JP2011526480A5 (enExample)
JP7486810B2 (ja) ＩｇＧ１ Ｆｃモノマー、及びその使用
JP2020186248A5 (enExample)
Golay et al. Design and validation of a novel generic platform for the production of tetravalent IgG1-like bispecific antibodies
JP2021522162A5 (enExample)
CN112513097B (zh) 四价对称双特异性抗体
JP2017531427A5 (enExample)
JP2013529070A5 (enExample)
JP2015519375A5 (enExample)
JP2020505919A5 (enExample)
JP2014521313A5 (enExample)
JP2012532838A (ja) 安定化された免疫グロブリン定常ドメイン
CN111526887A (zh) 用于使血清中的蛋白质半衰期增加的组合物和方法
TWI918721B (zh) Egfr結合複合物及其製備和使用方法
JP2015520172A5 (enExample)
JP2019505565A5 (enExample)
CN111819200A (zh) 抗c-met抗体
JP2022540918A5 (enExample)
JP2024500335A5 (enExample)
EP4069298A1 (en) Composition of triaxial antibodies and method of making and using thereof